Premium
1 H NMR studies of human urine: Urinary elimination of the anticancer drug carboplatin
Author(s) -
Ranford John D.,
Sadler Peter J.,
Balmanno Katherine,
Newell David R.
Publication year - 1991
Publication title -
magnetic resonance in chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.483
H-Index - 72
eISSN - 1097-458X
pISSN - 0749-1581
DOI - 10.1002/mrc.1260291321
Subject(s) - carboplatin , chemistry , urine , drug , anticancer drug , nuclear magnetic resonance spectroscopy , creatinine , excretion , pharmacology , stereochemistry , chemotherapy , biochemistry , medicine , cisplatin
Abstract Samples of urine from a patient obtained before and after treatment with 300 mg of the anticancer drug [Pt(II)(NH 3 )2(CBDCA)] (carboplatin, “Paraplatin”, where CBCDA is 1,1‐dicarboxycyclobutane) have been analysed using 500 MHz 1D and 2D 1 H NMR spectroscopy. Peaks for the intact drug and the free ligand CBDCA have been assigned and are present in a mol ratio of ca. 5:1. Only about one half of the total Pt in the sample was present as intact drug. Relative to creatinine and citrate, the excretion of hippurate increased by a factor of ca. 4 after drug treatment. This work suggests that NMR spectroscopy can play a valuable rǒle in studies of carboplatin metabolism.